Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ondansetron + atropine + bupivacaine
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous, Intrathecal
01
Overview
A combination of medications used in anesthesia practice, particularly during spinal anesthesia. Ondansetron is a serotonin 5-HT3 receptor antagonist that helps prevent nausea, vomiting, and hypotension. Atropine is an anticholinergic agent that prevents bradycardia by blocking cholinergic receptors. Bupivacaine is a local anesthetic used for regional anesthesia. When used together, these medications have complementary effects in preventing and treating complications associated with spinal anesthesia, including hypotension, bradycardia, and asystole.
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)NaV alpha (Voltage-gated sodium channel alpha subunit family)mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on ondansetron + atropine + bupivacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ondansetron + atropine + bupivacaine.